Abstract 30P
Background
Immunotherapy has shown long-term benefits in advanced non-small cell lung cancer (NSCLC) patients. However, the clinical characteristics, prognosis, and selection of appropriate therapies for Long-Term Responders (LTR) to first-line PD-1/PD-L1 inhibitors remain undetermined.
Methods
A total of 413 advanced NSCLC patients from three medical centers were included in the study, conducted from June 1, 2015, to August 31, 2021. It examined clinicopathologic data, overall survival (OS) distributions, and treatment strategies involving immune checkpoint inhibitors.
Results
Among the patients, 213 (51.6%) were LTRs. PD-L1 expression ≥50% was observed in 39.1% of LTR patients, higher than in non-LTR patients (21.7%). After propensity score matching, Cox univariable analysis revealed pathological type (HR 0.563; 95% CI 0.391–0.811; P=0.002), bone metastasis (HR 1.820; 95% CI 1.278–2.590; P=0.001), and liver metastasis (HR 2.220; 95% CI 1.291–3.817; P=0.004) as significant predictors of LTR. The pathological type (HR 0.641; 95% CI 0.441–0.932; P=0.020), bone metastasis (HR 1.593; 95% CI 1.106–2.293; P=0.012), and liver metastasis (HR 1.820; 95% CI 1.046–3.165; P=0.034) were significant predictors of LTR in Cox multivariable analysis. Significantly difference showed in OS (P < 0.0001) for Pembrolizumab-chemotherapy of lung squamous cell carcinoma (LUSC) in LTR group compared with Sintilimab-chemotherapy.
Conclusions
Therefore, we undertook an investigation of LTR and non-LTR with advanced NSCLC and compared clinical characteristics and efficacy of PD-1/PD-L1 inhibitors between these groups, especially Pembrolizumab and Sintilimab, with the aim of exploring the unique clinical predictors and providing reference for the selection of ICI.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.